4-(hydroxymethyl)cubane-1-carboxylic acid | 1261296-29-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-(hydroxymethyl)cubane-1-carboxylic acid
• 英文别名: (1s,2R,3r,8S)-4-(hydroxymethyl)cubane-1-carboxylic acid
• CAS: 1261296-29-0
• 化学式: C₁₀H₁₀O₃
• 分子量: 178.188
• InChiKey: QXKQUDFIQCNKLM-UHFFFAOYSA-N

物化性质

• 沸点：
  371.2±15.0 °C(Predicted)
• 密度：
  2.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-(hydroxymethyl)cubane-1-carboxylic acid 在 氯化亚砜 、 硝酸 作用下， 以 甲醇 为溶剂， 反应 10.0h， 生成 N-(2-nitrooxyethyl)-4-nitrooxymethylcubane-1-carboxamide
  参考文献：
  名称：

  Cubane derivatives 10. Synthesis and molecular structures of nitroxymethylcubanes

  摘要：

  羟甲基古巴烷与硝酸反应生成相应的硝基甲基古巴烷。

  DOI：

  10.1007/s11172-010-0204-2
• 作为产物：
  描述：

  4-甲氧羰基立方烷羧酸 在 sodium tetrahydroborate 、 盐酸 作用下， 以 水 为溶剂， 反应 3.0h， 以89%的产率得到4-(hydroxymethyl)cubane-1-carboxylic acid
  参考文献：
  名称：

  Cubane derivatives 10. Synthesis and molecular structures of nitroxymethylcubanes

  摘要：

  羟甲基古巴烷与硝酸反应生成相应的硝基甲基古巴烷。

  DOI：

  10.1007/s11172-010-0204-2

文献信息

• BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190127358A1

  公开（公告）日：2019-05-02

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（I）的化合物： 或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物调节法尼索尔X受体（FXR）的活性，例如作为激动剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与FXR失调相关的疾病、紊乱或病况的方法，例如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• [EN] HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DU RÉCEPTEUR P2Y14
  申请人：US HEALTH

  公开号：WO2019157417A1

  公开（公告）日：2019-08-15

  Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X', Y', Z', and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.

  揭示了以下化合物的结构式（I）-（IX），用于治疗或预防对P2Y14R受体激动剂拮抗敏感的哺乳动物患者的疾病或紊乱，其中R1-R8、X、Y、Z、X'、Y'、Z'和A的定义如下，这些化合物可用于治疗炎症性疾病，如哮喘、囊性纤维化和肾脏的无菌性炎症。
• Cubane, Bicyclo[1.1.1]pentane and Bicyclo[2.2.2]octane: Impact and Thermal Sensitiveness of Carboxyl‐, Hydroxymethyl‐ and Iodo‐substituents
  作者：Madeleine A. Dallaston、Sevan D. Houston、Craig M. Williams

  DOI：10.1002/chem.202001658

  日期：2020.9.16

  impact sensitivity, more research into the safety profiles of cage scaffolds is required. Therefore, the impact sensitivity and thermal decomposition behavior of judiciously selected starting materials and synthetic intermediates of cubane, bicyclo[1.1.1]pentane (BCP), and bicyclo[2.2.2]octane (BCO) were evaluated via hammer test and sealed cell differential scanning calorimetry, respectively. Iodo‐substituted

  随着对用于生物活性分子发现的笼形基序的兴趣不断增强，并且最近披露了1,4-古巴-二羧酸的撞击敏感性，需要对笼形脚手架的安全性进行更多的研究。因此，通过锤击试验和密封电池评估了明智选择的起始原料和古巴，双环[1.1.1]戊烷（BCP）和双环[2.2.2]辛烷（BCO）的合成中间体的冲击敏感性和热分解行为差示扫描量热法。发现碘取代的体系对冲击更敏感，而羟甲基取代导致更快的热分解。Cubane更有可能对这些取代基具有冲击敏感性，其次是BCP，而所有BCO均无反应。
• Bridged bicyclic compounds as farnesoid X receptor modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10730863B2

  公开（公告）日：2020-08-04

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式 (I) 的化合物： 或其立体异构体、同系物或药学上可接受的盐或溶液，其中所有变量均如本文所定义。这些化合物可调节法尼类固醇 X 受体（FXR）的活性，例如作为激动剂。本发明还涉及包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与 FXR 失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• Exploration of Alternative Scaffolds for P2Y₁₄ Receptor Antagonists Containing a Biaryl Core
  作者：Young-Hwan Jung、Jinha Yu、Zhiwei Wen、Veronica Salmaso、Tadeusz P. Karcz、Ngan B. Phung、Zhoumou Chen、Sierra Duca、John M. Bennett、Steven Dudas、Daniela Salvemini、Zhan-Guo Gao、Donald N. Cook、Kenneth A. Jacobson

  DOI：10.1021/acs.jmedchem.0c00745

  日期：2020.9.10

  Various heteroaryl and bicyclo-aliphatic analogues of zwitterionic biaryl P2Y(14) receptor (P2Y(14)R) antagonists were synthesized, and affinity was measured in P2Y(14)R-expressing Chinese hamster ovary cells by flow cytometry. Given this series' low water solubility, various polyethylene glycol derivatives of the distally binding piperidin-4-yl moiety of moderate affinity were synthesized. Rotation of previously identified 1,2,3-triazole attached to the central m-benzoic acid core (25) provided moderate affinity but not indole and benzimidazole substitution of the aryl-triazole. The corresponding P2Y(14)R region is predicted by homology modeling as a deep, sterically limited hydrophobic pocket, with the outward pointing piperidine moiety being the most flexible. Bicyclic-substituted piperidine ring derivatives of naphthalene antagonist 1, e.g., quinuclidine 17 (MRS4608, IC50 approximate to 20 nM at hP2Y(14)R/mP2Y(14)R), or of triazole 2, preserved affinity. Potent antagonists 1, 7a, 17, and 23 (10 mg/kg) protected in an ovalbumin/Aspergillus mouse asthma model, and PEG conjugate 12 reduced chronic pain. Thus, we expanded P2Y(14)R antagonist structure-activity relationship, introducing diverse physical-chemical properties.